Genistein inhibits expressions of NADPH oxidase p22phox and angiotensin II type 1 receptor in aortic endothelial cells from stroke-prone spontaneously hypertensive rats

Hypertension Research

Volumn 27, Issue 9, 2004, Pages 675-683

  Xu, Jin Wen ^a   Ikeda, Katsumi ^a   Yamori, Yukio ^b  

^a MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

^b WHO Collaborating Ctr for Research   (Japan)

Author keywords

Angiotensin II type 1 receptor; Endothelium; NADPH oxidase p22phox subunit; Peroxisome proliferator activated receptor ; Phytoestrogen

Indexed keywords

3 NITROTYROSINE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANTIOXIDANT; ENDOTHELIN 1; FULVESTRANT; GENISTEIN; HORMONE RECEPTOR BLOCKING AGENT; NITROBLUE TETRAZOLIUM; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHYTOESTROGEN; PROTEIN P22; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SUPEROXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIOXIDANT ACTIVITY; AORTA; ARTERY ENDOTHELIUM; ARTICLE; CARDIOVASCULAR FUNCTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DOWN REGULATION; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SUBUNIT; ESSENTIAL HYPERTENSION; GENETIC TRANSCRIPTION; HYPOTHESIS; INCUBATION TIME; INHIBITION KINETICS; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; STROKE; TIME; TREATMENT OUTCOME; WESTERN BLOTTING;

ANGIOTENSIN II; ANILIDES; ANIMALS; AORTA, THORACIC; CELLS, CULTURED; CEREBROVASCULAR ACCIDENT; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; ESTRADIOL; ESTROGEN ANTAGONISTS; GENISTEIN; HYPERTENSION; MALE; MEMBRANE TRANSPORT PROTEINS; NADPH DEHYDROGENASE; NADPH OXIDASE; PHOSPHOPROTEINS; PPAR GAMMA; RATS; RATS, INBRED SHR; RECEPTOR, ANGIOTENSIN, TYPE 1; SIGNAL TRANSDUCTION; SUPEROXIDES; TYROSINE; VASOCONSTRICTOR AGENTS;

EID: 8844228956     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.27.675     Document Type: Article

References (57)

1. Barry-Lane PA, Patterson C, Merwe M, et al: p47 phox is required for atherosclerotic lesion progression in ApoE -/- mice. J Clin Invest 2001; 108: 1513-1522.
2. Sorescu D, Weiss D, Lassegue B, et al: Superoxide production and expression of NOX family proteins in human atherosclerosis. Circulation 2002; 105: 1429-1435.
3. Azumi H, Inoue N, Takeshita S, et al: Expression of NADH/NADPH oxidase p22(phox) in human coronary arteries. Circulation 1999; 100: 1494-1498.
4. Zalba G, Beaumont FJ, Jose GS, et al: Vascular NADH/NADPH oxidase is involved in enhanced superoxide production in spontaneously hypertensive rats. Hypertension 2000; 35: 1055-1061.
5. Beswick RA, Dorrance AM, Leite R, Webb RC: NADH/NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat. Hypertension 2001; 38: 1107-1111.
6. - and systolic blood pressure in mice. Circ Res 2001; 89: 408-414.
7. Zhang H, Schmeisser A, Garlichs CD, et al: Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: role of membrane-bound NADH-/NADPH-oxidases. Cardiovasc Res 1999; 44: 215-222.
8. Wattanapitayakul SK, Weinstein DM, Holycross BJ, Bauer JA: Endothelial dysfunction and peroxynitrite formation are early events in angiotensin-induced cardiovascular disorder. FASEB J 2000; 14 271-278.
9. Ma X-L, Gao F, Nelson AH, et al: Oxidative inactivation of nitric oxide and endothelial dysfunction in stroke-prone spontaneous hypertensive rats. J Pharmacol Exp Ther 2001; 298: 879-885.
10. Sohn HY, Raff U, Hoffmann A, et al: Differential role of angiotensin II receptor subtypes on endothelial superoxide formation. Br J Pharmacol 2000; 131: 667-672.
11. Zhang C, Hein TW, Wang W, Kuo L: Divergent roles of angiotensin II AT1 and AT2 receptors in modulating coronary microvascular function. Circ Res 2003; 92: 322-329.
12. Chabrashvili T, Kitiyakara C, Blau J, et al: Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. Am J Physiol Regul Integr Comp Physiol 2003; 285: R117-R124.
13. Kurzer MS, Xu X: Dietary phytoestrogens. Annu Rev Nutr 1997; 17: 353-381.
14. Setchell KDR, Cassidy A: Dietary isoflavones: biological effects and relevance to human health. J Nutr 1999; 129: 758S-767S.
15. Lichtenstein AH: Soy protein, isoflavones and cardiovascular disease risk. J Nutr 1998; 128: 1589-1592.
16. Clarkson TB: Soy, soy phytoestrogens and cardiovascular disease. J Nutr 2002; 132: 566S-569S.
17. Kuiper GGJM, Lemmen JG, Carlsson B, et al: Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 1998; 139: 4252-4263.
18. An J, Tzagarakis-Foster C, Scharschmidt TC, Lomri N, Leitman DC: Estrogen receptor β-selective transcriptional activity and recruitment of coregulators by phytoestrogens. J Biol Chem 2001; 276: 17808-17814.
19. Ruiz-Larrea MB, Mohan AR, Paganga G, Miller NJ, Bolwell GP, RiceEvans CA: Antioxidant activity of phytoestrogenic iosflavones. Free Radic Res 1997; 26: 63-70.
20. Wei H, Bowen R, Cai Q, Barnes S, Wang Y: Antioxidant and antiproliferative effect of the soybeen isoflavone genistein. Proc Soc Exp Biol Med 1995; 208: 124-130.
21. Djuric Z, Chen G, Doerge DR, Heilbrum LK, Kucuk O: Effect of soy isoflavone supplementation on markers of oxidative stress in men and women. Cancer Lett 2001; 172: 1-6.
22. Sierens J, Hartley JA, Campbell MJ, Leathem AJC, Woodside JV: Effect of phytoestrogen and antioxidants supplementation on oxidative DNA damage assessed using the comet assay. Mutat Res 2001; 485: 169-176.
23. Mizutani K, Ikeda K, Nishikata T, Yamori Y: Phytoestrogens attenuate oxidative DNA damage in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. J Hypertens 2000; 18: 1833-1840.
24. Rohrdanz E, Ohler S, Tran-Thi Q-H, Kahl R: The phytoestrogen daidzein affects the antioxidant enzyme system of rat hepatoma H411E cells. J Nutr 2002; 132: 370-375.
25. Mezei O, Banz WJ, Steger RW, Peluso MR, Winters TA, Shay N: Soy isoflavones exert antidiabetic and hypolipidemic effects through the PPAR pathways in obese Zucker rats and murine RAW 264.7 cells. J Nutr 2003; 133: 1238-1243.
26. Dang ZC, Audinot V, Papapoulos SE, Boutin JA, Lowik CWGM: PPARγ as a molecular target for the soy phytoestrogen genistein. J Biol Chem 2003; 278: 962-967.
27. McGuire PG, Orkin RW: Isolation of rat aortic endothelial cells by primary explant techniques and their phenotypic modulation by defined substrata. Lab Invest 1987; 57: 94-105.
28. 2+ in HeLa cells. J Med Dent Sci 2001; 48: 51-59.
29. Suh YA, Arnold RS, Lassegue B, et al: Cell transformation by the superoxide-generating oxidase Mox1. Nature 1999; 401: 79-81.
30. Wang HD, Pagano PJ, Du Y, et al: Superoxide anion from the adventitia of the rat thoracic aorta inactivates nitric oxide. Circ Res 1998; 82: 810-818.
31. Setchell KDR: Soy isoflavones - benefits and risks from nature's selective estrogen receptor modulators (SERMs). J Am Coll Nutr 2001; 20: 354S-362S.
32. 2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism 2001; 50: 3-11.
33. Takeda K, Ichiki T, Tokunou T, et al: Peroxisome proliferator-activated receptor γ activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation 2000; 102: 1834-1839.
34. Huang JT, Welch JS, Ricote M, et al: Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase. Nature 1999; 400: 378-382.
35. Kahler J, Ewert A, Weckmuller J, et al: Oxidative stress increases endothelin-1 synthesis in human coronary artery smooth muscle cells. J Cardiovasc Pharmacol 2001; 38: 49-57.
36. Imai T, Hirata Y, Emori T, Yanagisawa M, Masaki T, Marumo F: Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension 1992; 19: 753-757.
37. Chua BH, Chua CC, Diglio CA, Siu BB: Regulation of endothelin-1 mRNA by angiotensin II in rat heart endothelial cells. Biochim Biophys Acta 1993; 1178: 201-206.
38. Wanger AH, Schroeter MR, Hecker M: 17β-estradiol inhibition of NADPH oxidase expression in human endothelial cells. FASEB J 2001; 15: 2121-2130.
39. Dantas APV, Tostes RCA, Fortes ZB, Costa SG, Nigro N, Carvalho MHC: In vivo evidence for antioxidant potential of estrogen in microvessels of female spontaneously hypertentive rats. Hypertension 2002; 39: 405-411.
40. Ying CJ, Xu JW, Ikeda K, Takahashi K, Nara Y, Yamori Y: Tea polyphenols regulate nicotinamide adenine dinucleotide phosphate oxidase subunit expression and ameliorate angiotensin II-induced hyperpermeability in endothelial cells. Hypertens Res 2003; 26 823-828.
41. Nickenig G, Baumer AT, Grohe C, et al: Estrogen modulates AT1 receptor gene expression in vitro and in vivo. Circulation 1998; 97: 2197-2201.
42. Baumer AT, Wassmann S, Ahlboryl K, et al: Reduction of oxidative stress and AT1 receptor expression by the selective oestrogen receptor modulator idoxifene. Br J Pharmacol 2001; 134: 579-584.
43. Akiyama T, Ishida J, Nakagawa S, et al: Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987; 262: 5592-5595.
44. Touyz RM, Yao G, Schiffrin EL: c-Src induces phosphorylation and translocation of p47phox: role in superoxide generation by angiotensin II in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2003; 23: 981-987.
45. Nickenig G, Strehlow K, Baumer AT, et al: Negative feedback regulation of reactive oxygen species on AT1 receptor gene expression. Br J Pharmacol 2000; 131: 795-803.
46. Finking G, Lenz C, Schochat T, Hanke H: Reduction of post injury neointima formation due to 17β-estradiol and phytoestrogen treatment is not influenced by the pure synthetic estrogen receptor antagonist ICI 182,780 in vitro. BMC Cardiovasc Dis 2002; 2: 13. Open accessed at: http://www.biomedcentral.com/1471-2261/2 /13
47. Ma H, Sprecher HW, Kolattukudy PE: Estrogen-induced production of a peroxisome proliferator-activated receptor (PPAR) ligand in a PPARγ-expressing tissue. J Biol Chem 1998; 273: 30131-30138.
48. Ma H, Tam QT, Kolattukudy PE: Peroxisome proliferator-activated receptor γ1 (PPAR-γ1) as a major PPAR in a tissue in which estrogen induces peroxisome proliferation. FEBS Lett 1998; 434: 394-400.
49. Jackson SM, Parhami F, Xi XP, et al: Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol 1999; 19: 2094-2104.
50. Delerive P, Martin-Nizard F, Chinetti G, et al: Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 1999; 85: 394-402.
51. Sugawara A, Takeuchi K, Uruno A, et al: Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-γ in vascular smooth muscle cells. Endocrinology 2001; 142: 3125-3134.
52. Sugawara A, Takeuchi K, Uruno A, et al: Differential effects among thiazolidinediones on the transcription of thromboxane receptor and angiotensin II type 1 receptor genes. Hypertens Res 2001; 24: 229-233.
53. Law RE, Meehan WP, Xi XP, et al: Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 1996; 98: 1897-1905.
54. Squadrito F, Altavilla D, Morabito N, et al: The effect of the phytoestrogen genistein on plasma nitric oxide concentrations, endothelin-1 levels and endothelium dependent vasodilation in postmenopausal women. Atherosclerosis 2002; 163: 339-347.
55. Delerive P, Martin-Nizard F, Chinetti G, et al: Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 1999; 85: 394-402.
56. Satoh H, Tsukamoto K, Hashimoto Y, et al: Thiazolidine-diones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARγ on vascular endothelial function. Biochem Biophys Res Commun 1999; 254: 757-763.
57. Martin-Nizard F, Furman C, Delerive P, et al: Peroxisome proliferator-activated receptor activators inhibit oxidized low-density lipoprotein-induced endothelin-1 secretion in endothelial cells. J Cardiovasc Pharmacol 2002; 40: 822-831.